Earnings Releases·Nov 5, 2026, 8:15 AM ET

Intellia Therapeutics — Third Quarter 2026 Earnings Summary

Cash and marketable securities increased to $614.8 million as of September 30, 2026, from $605.1 million at year-end 2025, while net loss widened to $127.5 million from $101.3 million in the prior year quarter, driven by a $10.4 million unrealized investment loss and higher G&A expenses.
Collaboration revenue declined to $7.2 million from $13.8 million year-over-year due to reduced Regeneron contributions, though R&D expenses decreased to $83.3 million from $94.7 million primarily from lower external costs.
The company secured a non-dilutive senior secured term loan facility of up to $400 million in September and appointed a new Chief Medical Officer in October to support commercial readiness.
Lonvo-z remains on track for a March 10, 2027 PDUFA date with commercial launch targeted for Q1 2027, while MAGNITUDE-2 enrollment for nex-z in ATTRv-PN was completed ahead of schedule.
Existing cash resources and the new loan facility are projected to fund operations through 2028, well beyond the anticipated commercial launch of lonvo-z.